
    
      This is a prospective open-label pilot study evaluating the role of cenegermin-bkbj for the
      treatment of LSCD with associated neurotrophic keratopathy. Patient diagnosed with LSCD with
      neurotrophic cornea who have failed conventional treatment such as artificial tears are
      enrolled in the study after a 2 week washout period. Patient are then treated with
      cenegermin-bkbj over an 8 week period.
    
  